Drug that Prolongs Lives of Incurable Breast Cancer Patients Approved
Perjeta, a drug, has been approved by the National Institute for Health and Care Excellence (NICE) for routine use after five years of assessing the effectiveness of the drug. By this development, it means that incurable breast cancer patients can live an everyday life. And this drug will be used in NHS in England.
Before now, it had only been available through the Cancer Drugs Fund since 2013. As a result of this, many breast Cancer patients were not even given the option of using the drug.
The drug, Perjeta or Pertuzumab, will be used in combination with trastuzumab and a chemotherapy drug called docetaxel, to give men and women with secondary breast cancer a relatively normal life.
Scotland, last year, refused to make Perjeta available on the NHS as it could not justify the “cost in relation to its health benefits.”
Sarah Hepworth, a cancer patient, who has been a beneficial of Perjeta posited while speaking with Newsmen that:
“I was initially on chemotherapy which was horrific, I had terrible side effects and I wasn’t living, just surviving.
“When I was put on Perjeta, with two other drugs, it gave me a new lease of life and I really don’t have the side effects.
“I now live a normal life, a new normal where I live by my last scan, but normal nonetheless. She concluded.